Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

NCT02914626 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Glaucoma, Neovascular
Ranibizumab

Interventions

DRUG: Intravitreal ranibizumab

Sponsor

LEANDRO CABRAL ZACHARIAS

Collaborators

[object Object]